The confident answers on Semaglutide formulation and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Everything in post #6 holds. The case it does not cover is the one I have.
Where I have landed on Semaglutide formulation, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
Building on post #21 rather than restating it.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Reading it again, the caveat matters more than the finding.
Building on post #26 rather than restating it.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
Genuine question rather than a rhetorical one: has anyone here actually observed Semaglutide formulation, as opposed to read about it? The thread is long and I cannot tell.
Worth separating two things that post #50 runs together.
Practical note on Semaglutide formulation: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Confirming post #58 from a second method, which matters more than confirming it from a second person.
Worth separating Semaglutide formulation as a question about the compound from Semaglutide formulation as a question about the documentation. They get answered by different people and only one of them is answerable here.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Everything in post #67 holds. The case it does not cover is the one I have.
The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.
I would want to see it done twice before believing it once.
Read the full topic (78 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset
Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Two things I would like separated before…
|
+112 | 130 | 2.2k | 16mo |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…
|
+58 | 62 | 49k | 20mo |
|
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I would like to know what people here actually do about semaglutide…
|
+14 | 18 | 10k | 2d |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. Semaglutide and gastric emptying,…
|
+115 | 122 | 2.6k | 1d |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: What pooling buys you and what it destroys
On the subject in the title: Revisiting: What pooling buys you and what it destroys Working notes rather than a conclusion. Pooling buys — I have the observation and I do not trust my interpretation of it, so…
|
+97 | 107 | 4k | 19h |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |
|
Preprint servers and what screening they do
Preprint servers and what screening they do — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The manuscript is on a…
|
+95 | 106 | 5.6k | 4mo |
|
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. The question about STEP 4 that I actually want…
|
+81 | 90 | 54k | 9mo |
|
Second pass at: Regression to the mean in progress reports
Second pass at: Regression to the mean in progress reports Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Regression. It is mine, it is…
|
+71 | 75 | 4k | 17mo |